Evaluation of platelet function following cessation of ticagrelor - a study in patients with acute coronary syndrome and PCI with coronary stent
- Conditions
- Return of platelet function following cessation of oral anti-platelet treatment with ticagrelor.Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
- Registration Number
- EUCTR2012-000665-20-SE
- Lead Sponsor
- niversitetssjukhuset Örebro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. 12 months (+/- one week) treatment with double platelet blockade in the form of ASA and ticagrelor following PCI
2. Age = 45 years
3. Signed and dated Informed Consent
4. The subject is willing and judged capable of following the protocol throughout the study period
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 0
1. Resistance against ticagrelor treatment (so-called non-responders”)
2. Other oral anti-platelets agents other than ticagrelor 180 mg and ASA 75 mg/day
3. Concurrent treatment with fluvoxamine, fluoxetine, moklobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxkarbazepine or chloramphenicol.
4. Oversensitivity/allergy to ticagrelor
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method